ENTA — Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals Inc (ENTA) is a biotechnology company listed on NASDAQ. It is led by Jay R. Luly Ph.D., based in 4 Kingsbury Avenue, Watertown, MA, United States, 02472, with about 120 employees. Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Latest reported ENTA revenue for 2025-09-30 was $65.3M. Net income was -$81.9M. Revenue was up 256.7% from 2025-06-30 to 2025-09-30. ENTA currently screens at market cap $328.0M.

Use this ENTA page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ENTA quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ENTA SEC filings page. Lician reads the product cache first so this HTML stays unique to Enanta Pharmaceuticals Inc even when a live quote feed is slow.